Farxiga (dapagliflozin) is a type 2 diabetes oral medication in the SGLT-2 inhibitor class of drugs. It blocks glucose from being reabsorbed by the kidneys. Excess glucose is released in the urine. Medications in the SGLT-2 inhibitor class may offer heart and kidney benefits for people with cardiovascular disease.
Farxiga is approved for adults and children aged 10 years and older with type 2 diabetes.
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.